MIST · sample dossier
Milestone Pharmaceuticals Inc. Common Shares
30/100
OutdatedGenerated Oct 5, 2026 · 6:00 AM UTC · 19 hours ago
This copy is frozen (Oct 5). Sign in to run the same work — filings, valuation, bull and bear, sources — on any US stock or ETF, in about a minute.
Run a fresh dossierMIST
EquityMilestone Pharmaceuticals Inc. Common SharesXNAS
What changed recently
No material filings in the last 30 days
Decision context
AVOID
35% convictionScore 30 · Avoid
Downsides look heavier than upsides — we wouldn’t start a new position.
No estimated value range on this report
Current price
$0.81
Estimated value range
—
Gap (vs price at analysis)
—
AlphaDog could not produce an estimate from comps or DCF. Analyst targets are shown separately and are not the AlphaDog estimate.
Estimated value range is unavailable for this instrument.
Market context
Price
Price when available
Pick how far back the chart looks
1 month
-31.4%
3 months
-38.6%
6 months
-41.3%
1 year
-60.5%
Financial trajectory
Executive summary & thesis
Milestone Pharmaceuticals Inc. is a micro-cap biopharmaceutical company with a market capitalization of $100.81M and an enterprise-value-to-EBITDA multiple of -1.09.
- Gross margin is exceptionally high at 98.0%, providing substantial operational leverage if commercial sales scale.
- Commercial launch progress for CARDAMYST (etripamil) nasal spray was formally announced via Form 8-K on 2026-03-20.
- CFO Amit Hasija purchased 20,100 shares on 2026-01-26, though this insider transaction is stale data older than 90 days.
- Balance sheet distress is critical with an Altman Z-score of 0.6 alongside negative free cash flow per share of $-0.33.
- Shareholders suffered massive dilution from a 109.2% YoY increase in common shares outstanding.
- Capital structure leverage is elevated with a Debt/Equity ratio of 7.79 and an ROA of -42.8%.
Things to keep in mind
- 1P/E -1.2xView source
- 2Debt/Equity 7.79View source
- 3Net margin 0.0%View source
What to watch next
Factor profile
Turnaround profile
| Factor | Score |
|---|---|
| Quality | 31 out of 100 (Weak). Business health — profits, returns, and consistency. Higher means a more durable company. |
| Growth | 50 out of 100 (Neutral). How fast sales and earnings are rising. Higher means the business is expanding faster. |
| Value | 34 out of 100 (Weak). How cheap the stock looks for what you get. Higher means a more attractive price. |
| Safety | 26 out of 100 (Weak). Balance-sheet cushion and fewer red flags. Higher means less risk of a nasty surprise. |
| Momentum | 0 out of 100 (Weak). Recent share-price trend. Higher means buyers have been in control lately. |
Another way to look at it
What the optimistic case might still be missing about MIST
The unanimous bear consensus dismisses Milestone Pharmaceuticals on textbook distress signals that mischaracterize an early-stage commercial biopharmaceutical inflection.
While an Altman Z-score of 0.60 and a Debt/Equity ratio of 7.79 reflect historical development-stage cash burn, they ignore the operating leverage embedded in a 98.0% gross margin. Furthermore, the extreme Beneish M-score reading of 1,113,115.4 is a statistical artifact of revenue emerging off a near-zero base rather than genuine accounting fabrication. Revenue expanded 134.9% sequentially from $238,000 in Q1 2026 to $559,000 in Q2 2026 following the commercial launch of CARDAMYST. Although 109.2% YoY share dilution and -$0.33 free cash flow per share present legitimate dilution risks, the -60.5% 1-year drawdown already prices in insolvency, creating an asymmetric recovery profile if commercial distribution accelerates.
The bear consensus relies heavily on an Altman Z-score of 0.60 and Debt/Equity of 7.79 without adjusting for typical pre-commercial clinical biotech debt structures that are frequently renegotiated post-launch.
The screening engine flags an anomalous Beneish M-score of 1,113,115.4 as earnings manipulation, overlooking that non-linear commercial revenue scaling from $238,000 to $559,000 mechanically breaks traditional accrual ratio models.
Institutional retention by specialized biopharma funds Pavaki Capital (9.1M shares) and RTW Investments (7.8M shares) suggests ongoing structural sponsor access that the Avoid consensus treats as absent.
Bull arguments extrapolate a 98.0% gross margin as sustained operating leverage without factoring in CARDAMYST commercialization overhead, marketing spend, or distribution partner cuts.
The bull case relies on sequential quarterly revenue growth to $559,000, which represents an annualized commercial run-rate of barely $2.24M against ongoing losses of -$0.21 per share.
Despite a 1-year price performance of -60.5% and the stock trading below both MA50 and MA200, media sentiment remains disproportionately positive with 9 bullish and 19 neutral articles out of 28.
Debt/Equity ratio declines below 7.79 alongside free cash flow per share turning positive from $-0.33.
ROA rebounds above -42.8% toward breakeven.
Cash after investing
See whether MIST still makes cash after it spends to grow.
- Debt/Equity ratio declines below 7.79 alongside free cash flow per share turning positive from $-0.33.
- ROA rebounds above -42.8% toward breakeven.
- Net margin expands above 0.0% for two consecutive quarters
For learning and research only — not investment advice. AlphaDog doesn’t hold stocks and isn’t your financial advisor.
Run the next one yourself.
You just read a full MIST dossier — scored verdict, valuation, and both sides, with sources. Sign in to run that on a name you hold, on current filings. A free account includes 10 credits a week, 1 per fresh run.